Message from the Director

Dear Friends and Colleagues:

The past 17 years have been a time of significant progress in the care of patients with Multiple Myeloma. Our Myeloma program in Arkansas has developed innovations that have taken us directly from research to the treatment of patients who represent all age groups, nationalities and levels of disease. The tremendous strides we have made in changing the outcome for Myeloma patients, stem from novel research and its applications, including:

• Combination chemotherapy using VAD (Vincristine, Adriamycin, Dexamethasone)

• Bone marrow and peripheral blood stem cell transplants

• Tandem bone marrow transplants with increased remission rates

• Bone marrow transplants for patients over the age of 70

• Transplants for patients with severe renal disease

• Introduction of Thalidomide as a treatment for Myeloma

• Cytogenetic research to identify chromosomal prognostic factors

• Genetic chip analysis at the cutting edge of genomic science

The phenomenal growth of the Myeloma program at UAMS is marked by distinct milestones:

• More than 7,000 bone marrow transplants have been performed

• More than 7,400 new patients have come to Arkansas to be treated for Myeloma

• More than 200 peer-reviewed publications have gone to press from the Myeloma clinical and research staff

• More than 40 countries on six continents are represented in our patient population

The team approach we use in treating Myeloma will be of great benefit to you. Our physicians, nurses and other support staff all work together to offer a comprehensive approach to your care. Please read on throughout this website to learn how our unique program can benefit you and your loved ones.

Sincerely,

Bart Barlogie, MD

Having problems with the site? E-mail the Webmaster.
Copyright 2002-2005, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences
Terms and Conditions of Use

The information on the Myeloma Institute web site is not intended as a substitute for professional medical attention. The information is intended only as an aid in understanding current medical knowledge. A physician should always be consulted for any health concern or medical condition. The Myeloma Institute web site provides links to other organizations as a service to our readers. The Myeloma Institute is not responsible for the information provided on other web sites.